FibroGen, Inc.
NASDAQ:FGEN
0.3189 (USD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 147.752 | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 | 125.668 | 179.577 | 180.828 | 137.601 | 102.17 | 65.933 |
| Cost of Revenue
| 18.848 | 20.28 | 12.871 | 8.869 | 1.147 | 235.839 | 196.517 | 187.206 | 214.089 | 150.794 | 85.71 | 74.222 |
| Gross Profit
| 128.904 | 120.454 | 222.438 | 167.45 | 255.43 | -22.881 | -70.849 | -7.629 | -33.261 | -13.193 | 16.46 | -8.289 |
| Gross Profit Ratio
| 0.872 | 0.856 | 0.945 | 0.95 | 0.996 | -0.107 | -0.564 | -0.042 | -0.184 | -0.096 | 0.161 | -0.126 |
| Reseach & Development Expenses
| 282.861 | 296.791 | 387.043 | 252.924 | 209.265 | 235.839 | 196.517 | 187.206 | 214.089 | 150.794 | 85.71 | 74.222 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 63.812 | 51.76 | 46.025 | 44.364 | 36.909 | 24.409 | 18.934 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 115.252 | 124.688 | 123.925 | 106.406 | 135.479 | 63.812 | 51.76 | 46.025 | 44.364 | 36.909 | 24.409 | 18.934 |
| Other Expenses
| -294.891 | 0 | 0 | 0 | 0 | 42.161 | 0 | 0 | 0 | 0.016 | 0.156 | 0.181 |
| Operating Expenses
| 398.113 | 421.479 | 510.968 | 359.33 | 344.744 | 299.651 | 248.277 | 233.231 | 258.453 | 187.703 | 110.119 | 93.156 |
| Operating Income
| -269.209 | -301.025 | -288.53 | -191.88 | -89.314 | -86.693 | -122.609 | -53.654 | -77.625 | -50.102 | -7.949 | -27.223 |
| Operating Income Ratio
| -1.822 | -2.139 | -1.226 | -1.088 | -0.348 | -0.407 | -0.976 | -0.299 | -0.429 | -0.364 | -0.078 | -0.413 |
| Total Other Income Expenses Net
| -17.658 | 6.156 | -2.153 | 2.949 | 12.672 | 0.577 | -3.273 | -8.097 | -7.912 | 0.016 | 0.156 | 0.181 |
| Income Before Tax
| -286.867 | -294.869 | -290.683 | -188.931 | -76.642 | -86.116 | -125.882 | -61.751 | -85.537 | -59.504 | -14.943 | -32.671 |
| Income Before Tax Ratio
| -1.942 | -2.095 | -1.235 | -1.072 | -0.299 | -0.404 | -1.002 | -0.344 | -0.473 | -0.432 | -0.146 | -0.496 |
| Income Tax Expense
| 0.003 | 0.358 | 0.347 | 0.36 | 0.328 | 0.304 | 0.321 | -0.071 | 0.242 | 11.124 | 10.858 | -0.1 |
| Net Income
| -284.232 | -295.227 | -291.03 | -189.291 | -76.97 | -86.42 | -126.203 | -61.68 | -85.779 | -59.504 | -14.943 | -32.571 |
| Net Income Ratio
| -1.924 | -2.098 | -1.237 | -1.074 | -0.3 | -0.406 | -1.004 | -0.343 | -0.474 | -0.432 | -0.146 | -0.494 |
| EPS
| -2.92 | -3.15 | -3.15 | -2.11 | -0.89 | -1.03 | -1.73 | -0.98 | -1.42 | -3.17 | -0.32 | -0.69 |
| EPS Diluted
| -2.92 | -3.15 | -3.15 | -2.11 | -0.89 | -1.03 | -1.73 | -0.98 | -1.42 | -3.17 | -0.32 | -0.69 |
| EBITDA
| -259.279 | -282.825 | -288.53 | -186.327 | -73.766 | -75.125 | -116.176 | -44.986 | -74.504 | -43.926 | 0.843 | -17.047 |
| EBITDA Ratio
| -1.755 | -2.01 | -1.226 | -1.057 | -0.288 | -0.353 | -0.924 | -0.251 | -0.412 | -0.319 | 0.008 | -0.259 |